Table 3.
Crude and Adjusted Incidence Rate Ratios for Noncommunicable Diseases Among Antiretroviral Therapy–Experienced, HIV-Infected Adults by Age, Sex, and Race, 2000–2013
| Age Group, y | Univariate Analysis | Multivariable Analysisa | ||
|---|---|---|---|---|
| IRR | (95% CI) | aIRR | (95% CI) | |
| Hypertension (n = 68405) | ||||
| Non-black women | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 1.7 | (1.3–2.3) | 1.6 | (1.2–2.2) |
| 50–59 | 2.8 | (2.1–3.7) | 2.5 | (1.7–3.5) |
| 60–69 | 2.9 | (1.8–4.6) | 2.2 | (1.2–4.1) |
| Black women | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 2.0 | (1.7–2.3) | 1.6 | (1.3–1.9) |
| 50–59 | 2.4 | (1.9–2.9) | 1.6 | (1.2–2.2) |
| 60–69 | 1.6 | (1.0–2.7) | 1.1 | (.5–2.5) |
| Non-black men | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 2.0 | (1.9–2.2) | 1.9 | (1.7–2.2) |
| 50–59 | 3.2 | (2.9–3.5) | 2.5 | (2.2–2.9) |
| 60–69 | 4.1 | (3.7–4.6) | 3.0 | (2.4–3.8) |
| Black men | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 2.0 | (1.8–2.2) | 1.8 | (1.5–2.1) |
| 50–59 | 2.9 | (2.6–3.2) | 2.4 | (1.9–2.9) |
| 60–69 | 3.6 | (3.1–4.1) | 2.4 | (1.0–1.4) |
| Type 2 diabetes (n = 86789) | ||||
| Non-black women | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 1.8 | (1.4–2.4) | 1.4 | (.9–2.1) |
| 50–59 | 2.4 | (1.8–3.3) | 2.4 | (1.5–3.7) |
| 60–69 | 2.5 | (1.6–4.0) | 1.9 | (1.0–3.9) |
| Black women | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 1.7 | (1.4–2.0) | 1.5 | (1.1–2.1) |
| 50–59 | 2.1 | (1.8–2.6) | 1.6 | (1.1–2.3) |
| 60–69 | 2.7 | (1.9–3.8) | 2.8 | (1.7–4.8) |
| Non-black men | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 2.2 | (1.9–2.5) | 2.0 | (1.6–2.5) |
| 50–59 | 3.7 | (3.2–4.2) | 3.4 | (2.7–4.3) |
| 60–69 | 4.6 | (3.9–5.3) | 4.7 | (3.5–6.2) |
| Black men | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 1.9 | (1.7–2.2) | 1.3 | (1.0–1.8) |
| 50–59 | 2.7 | (2.3–3.1) | 1.8 | (1.3–2.5) |
| 60–69 | 3.1 | (2.6–3.7) | 2.8 | (1.9–4.2) |
| Chronic kidney disease (n = 52411) | ||||
| Non-black women | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 3.2 | (1.9–5.6) | 2.7 | (1.3–5.6) |
| 50–59 | 4.5 | (2.4–8.3) | 3.9 | (1.7–8.9) |
| 60–69 | 14.3 | (7.4–27.8) | 16.7 | (6.9–40) |
| Black women | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 2.5 | (1.7–3.6) | 1.7 | (1.0–2.8) |
| 50–59 | 4.3 | (2.9–6.4) | 3.6 | (2.1–6.2) |
| 60–69 | 7.0 | (3.9–12.5) | 8.1 | (3.9–16.6) |
| Non-black men | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 4.1 | (3.0–5.5) | 3.7 | (2.4–5.5) |
| 50–59 | 8.4 | (6.2–11.4) | 7.3 | (4.8–11.1) |
| 60–69 | 22.1 | (16.1–30.4) | 16.8 | (10.4–26.9) |
| Black men | ||||
| <40 | 1 | Ref | 1 | Ref |
| 40–49 | 2.0 | (1.5–2.7) | 1.6 | (1.0–2.6) |
| 50–59 | 4.5 | (3.4–5.9) | 4.0 | (2.5–6.6) |
| 60–69 | 8.8 | (6.4–12.0) | 9.6 | (5.2–17.5) |
Confidence intervals that do not overlap 1 are shown in bold.
Abbreviations: aIRR, adjusted incidence rate ratio; CI, confidence interval; IRR, incidence rate ratio; Ref = reference.
a
Adjusted Poisson analyses controlled for injection drug use, history of smoking, calendar year at antiretroviral therapy (ART) initiation, cohort, AIDS at entry, time-updated CD4 count, and the combined variable for ART and viremia status (where viral suppression ≤400 copies/mL).